Lia Gore, MD
Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation

Photo
Medical School:
  • MD, George Washington University School of Medicine and Health Sciences (1993)
Undergraduate School:
  • BA, Carleton College (MN) (1987)
Internship:
  • George Washington University/Children's National Medical Center Program (1994)
Residencies:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatrics (1996)
  • George Washington University/Children's National Medical Center Program, Pediatrics (1994)
Fellowships:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (1999)
  • University of Colorado (Children's Hospital Colorado) Program, Leukemia Biology (2001)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation

Professional Titles

  • Section Head, Pediatric Hematology/Oncology/BMT
  • Ergen Family Chair in Pediatric Oncology
  • Co-Director, Developmental Therapeutics Program, University of Colorado Cancer Center

Recognition & Awards

  • 5280 Top Docs, 5280 Magazine (2017)
  • 5280 Top Docs, 5280 Magazine (2016)
  • America's Top Oncologists, Consumers Research Council of America (2016)
  • 5280 Top Docs, 5280 Magazine (2015)
  • America's Top Oncologists, Consumers Research Council of America (2015)
  • 5280 Top Docs, 5280 Magazine (2014)
  • America's Top Oncologists, Consumers Research Council of America (2014)
  • America's Top Oncologists, Consumers Research Council of America (2013)
  • 5280 Top Docs, 5280 Magazine (2012)
  • America's Top Oncologists, Consumers Research Council of America (2012)
  • Distinguished Achievement Award, Carleton College (2012)
  • America's Top Oncologists, Consumers Research Council of America (2011)
  • America's Top Oncologists, Consumers Research Council of America (2010)
  • America's Top Oncologists, Consumers Research Council of America (2009)
  • America's Top Oncologists, Consumers Research Council of America (2008)
  • New Inventor of the Year, University of Colorado (2007)
  • America's Top Oncologists, Consumers Research Council of America (2007)

Research Interests

I am interested in Phase I clinical trials and Clinical-Translational Research in novel cancer treatments, with a particular emphasis on leukemias, sarcomas, and pediatric brain tumors.

Publications

  • Sun W, Triche T Jr., Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium. Blood. 2018 Jan 16. [Epub ahead of print] PubMed PMID: 29339403
  • Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 Jan 20. [Epub ahead of print] PubMed PMID: 28105566
  • Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer. 2017 Dec 19. [Epub ahead of print] PubMed PMID: 29266189
  • Mejstríková E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, Zugmaier G, Gore L, von Stackelberg A, Locatelli F. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017 Dec 20;7(12):659. PubMed PMID: 29259173
  • Maloney KW, Gore L. Agents in Development for Childhood Acute Lymphoblastic Leukemia. Paediatr Drugs. 2017 Nov 15. [Epub ahead of print] PubMed PMID: 29143289
  • Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017 Nov;86:358-363. PubMed PMID: 29100190
  • Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017;9:108. PubMed PMID: 29034009
  • Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20;35(33):3737-3744. PubMed PMID: 28968170
  • Gore L, Ivy SP, Balis FM, Rubin E, Thornton K, Donoghue M, Roberts S, Bruinooge S, Ersek J, Goodman N, Schenkel C, Reaman G. Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. J Clin Oncol. 2017 Nov 20;35(33):3781-3787. PubMed PMID: 28968169
  • Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2017 Sep 8. [Epub ahead of print] PubMed PMID: 28887726
  • Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters BK, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. J Neuropathol Exp Neurol. 2017 Sep 1;76(9):779-788. PubMed PMID: 28859336
  • Gore L. Drug development for rare cancers in children. Clin Adv Hematol Oncol. 2017 Jun;15(6):441-443. PubMed PMID: 28749903
  • Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov;64(11). PubMed PMID: 28544128
  • Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer. 2017 Aug;64(8). PubMed PMID: 28409853
  • Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 Aug;35(4):471-477. PubMed PMID: 28105566
  • von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. PubMed PMID: 27998223
  • Awan FT, Gore L, Gao L, Sharma J, Lager J, Costa LJ. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. Br J Haematol. 2016 Oct;175(1):55-65. PubMed PMID: 27293194
  • Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15;22(16):4014-22. PubMed PMID: 26920889
  • Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 Jul;62:9-17. PubMed PMID: 27185573
  • Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, Kleinschmidt-DeMasters BK, Johnston JM, Anderson RC, Rosenfeld A, Handler M, Gore L, Foreman N, Hankinson TC. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun. 2015 May 21;3:30. PubMed PMID: 25990246
  • Ashley D, Thomas D, Gore L, Carter R, Zalcberg JR, Otmar R, Savulescu J. Accepting risk in the acceleration of drug development for rare cancers. Lancet Oncol. 2015 Apr;16(4):e190-4. PubMed PMID: 25846099
  • Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar;62(3):414-8. PubMed PMID: 25407157
  • Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug;99(8):1277-84. PubMed PMID: 25082785
  • Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. PubMed PMID: 24962521
  • Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1( ) leukemia. Am J Hematol. 2014 Sep;89(9):896-903. PubMed PMID: 24891015
  • Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, Smith A, Cohen K, Kuttesch J, Strother D, Baruchel S, Gammon J, Kowalski M, Bouffet E. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014 Nov;16(11):1554-9. PubMed PMID: 24847085
  • Hoffman LM, Gore L. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014;4:63. PubMed PMID: 24744989
  • Faulk K, Gore L, Cooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Paediatr Drugs. 2014 Jun;16(3):213-27. PubMed PMID: 24639021
  • Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 May;73(5):951-60. PubMed PMID: 24633809
  • Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik A. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs. 2014 Aug;32(4):653-60. PubMed PMID: 24604265
  • Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. PubMed PMID: 24493827
  • Hoffman LM, Gore L, Maloney KW. Pulmonary presentation of relapsed acute myeloid leukemia. J Pediatr Hematol Oncol. 2014 Apr;36(3):228-30. PubMed PMID: 23619108
  • Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendran A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L, on behalf of the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2013 Feb;60(2):230-236. PubMed PMID: 23024067
  • Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb;31(1):115-25. PubMed PMID: 22415798
  • Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatr Blood Cancer. 2012 Dec 15;59(7):1252-8. PubMed PMID: 22887831
  • Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012 Oct;30(5):1942-9. PubMed PMID: 21931969
  • Macy ME, DeRyckere D, Gore L. Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. Invest New Drugs. 2012 Apr;30(2):468-79. PubMed PMID: 21046425
View All (37 Total) View Less

Professional Memberships

  • American Society of Hematology, Full Member
  • American Association of Cancer Research, Full Member
  • American Society of Clinical Oncology, Full Member
  • Children’s Oncology Group, Member
  • University of Colorado Cancer Center, Member
  • American Society of Pediatric Hematology/Oncology, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

UCH - Anschutz Outpatient Pavilion
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

UCH - Cancer Center
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • Children's Hospital Colorado
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Pediatric Hematology / Oncology, Board Certification (2001, 2017)
  • Pediatrics, Board Certification (1996, 2003)
  • PALS, Certificate (2017)
  • BLS, Certificate (2017)
  • American Board of Pediatrics - Hematology/Oncology Sub-Board, Board Certification (2000)
  • American Board of Pediatrics, Board Certification (1996)
Conditions & Treatments
  • Blood / Lymphatic System - Blood Disorders
  • Blood / Lymphatic System
  • Cancers
  • Brain and Nervous System - Brain Tumors
  • Cancers - Bone Cancer
  • Cancers - Brain Cancer
  • Cancers - Cancer Medicine
  • Cancers - Chemotherapy
  • Cancers - Leukemia (Adult Acute)
  • Cancers - Leukemia (Adult Chronic)
  • Cancers - Leukemia (Childhood)
  • Cancers - Lung Cancer
  • Cancers - Lymphoma
  • Cancers - Pediatric Cancer
  • Brain and Nervous System
Clinical Interests
I am interested in Phase 1 Clinical Trials with Special Emphasis on Acute Leukemias/Bone Marrow Transplant, Sarcomas, and Brain Tumors.

Care Philosophy
I believe that each patient and each family requires an individual approach appropriate to the needs and situation being faced. I work hard to ensure that the best and most complete information is available and try to work toward solutions and plans that meet any person at the level at which they are most comfortable. I believe in a team-based approach that brings the best minds and ideas together to find the best options available.

Volunteer Activities
Round Up River Ranch: a SeriousFun Network Camp Carleton College Denver Public Schools The Logan School Hinote's Heroes

Public Speaking
Yes

General Information

Medical Schools:
  • MD, George Washington University School of Medicine and Health Sciences (1993)
Undergraduate Schools:
  • BA, Carleton College (MN) (1987)
Internships:
  • George Washington University/Children's National Medical Center Program (1994)
Residency Programs:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatrics (1996)
  • George Washington University/Children's National Medical Center Program, Pediatrics (1994)
Fellowships:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (1999)
  • University of Colorado (Children's Hospital Colorado) Program, Leukemia Biology (2001)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation
;